Last Update Time:
28-Feb-2025 16:00:00
ISIN:
INE935A01035
Sector:
Healthcare
Symbol:
GLENMARK
Glenmark Pharmaceuticals Limited
₹1,284.15
₹-29.20
(-2.22%)
▼
Prev. Close
₹1,313.35
Open
₹1,301.55
Close
₹1,278.95
Range
₹1,219.94 - ₹1,348.36
High
₹1,310.00
Low
₹1,275.50
Ind. Close
₹0.00
VWAP
₹1,286.15
The current stock price of Glenmark Pharmaceuticals Limited is ₹1,284.15, with a target price range between ₹1,219.94 and ₹1,348.36. The stock has experienced a price change of ₹-29.20 (-2.22%), reflecting recent market volatility.
Today's opening price was ₹1,301.55, while the previous close stood at ₹1,313.35.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Glenmark Pharmaceuticals Limited Price Chart
Glenmark Pharmaceuticals Limited Pre Open Market Overview: 28-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1301.55
- Previous Close Price: 1313.35
- Change: -11.80%
- Total Traded Volume: 71
- Total Buy Quantity: 1,542
- Total Sell Quantity: 5,979
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,296.65 | 5.00 | 0.00 |
| 1,297.10 | 1.00 | 0.00 |
| 1,298.00 | 1.00 | 0.00 |
| 1,300.00 | 150.00 | 0.00 |
| 1,300.05 | 50.00 | 0.00 |
| 1,301.55 | 0.00 | 6.00 |
| 1,301.60 | 0.00 | 8.00 |
| 1,304.45 | 0.00 | 8.00 |
| 1,306.80 | 0.00 | 100.00 |
| 1,307.30 | 0.00 | 8.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1542
Total Sell Quantity: 5979
Shareholding Patterns of Glenmark Pharmaceuticals Limited
Key Trade Statistics of Glenmark Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 6.98 |
| Traded Value (₹ Cr.) | 89.77 |
| Total Market Cap (₹ Cr.) | 36,237.19 |
| Free Float Market Cap (₹ Cr.) | 19,298.41 |
| Impact cost | 0.04 |
| Quantity Traded | 697,953.00 |
| Deliverable Quantity | 389,158.00 |
| % of Quantity to Traded | 55.76 |
| Security VaR | 12.72 |
| Index VaR | N/A |
| VaR Margin | 12.72 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 16.22 |
| Face Value | 1 |
Key Price Statistics of Glenmark Pharmaceuticals Limited
The 52-week high for Glenmark Pharmaceuticals Limited was ₹1,830.95, recorded on 15-Oct-2024. On the other hand, the 52-week low stands at ₹883.00, with the lowest value recorded on 14-Mar-2024.
The upper band for trading is ₹1,444.65, and the lower band is ₹1,182.05. The price band is No Band%.
The stock's daily volatility stands at 2.00, while the annualized volatility is 38.21. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (15-Oct-2024) | 1,830.95 |
| 52 Week Low (14-Mar-2024) | 883.00 |
| Upper Band | 1,444.65 |
| Lower Band | 1,182.05 |
| Price Band (%) | No Band |
| Daily Volatility | 2.00 |
| Annualised Volatility | 38.21 |
| Tick Size | 0.05 |
Key Securities Statistics of Glenmark Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 07-Feb-2000 |
| Adjusted P/E | NA |
| Symbol P/E | NA |
| Index | NIFTY PHARMA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Glenmark Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Glenmark Pharmaceuticals Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Press Release | 27-Feb-2025 |
| General Updates | 24-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 19-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 17-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 17-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 14-Feb-2025 |
| Integrated Filing- Financial | 14-Feb-2025 |
Corporate Actions of Glenmark Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Dividend - Rs 2.50 Per Share | 13-Sep-2024 |
| 1 | Dividend - Rs 2.50 Per Share | 18-Sep-2023 |
| 1 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 12-Sep-2022 |
| 1 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 08-Sep-2021 |
| 1 | Annual General Meeting/Dividend - Rs 2.50 Per Share | 17-Sep-2020 |
| 1 | Annual General Meeting/Dividend - Rs 2 Per Share | 19-Sep-2019 |
| 1 | Annual General Meeting/Dividend Rs 2 Per Share | 19-Sep-2018 |
| 1 | Annual General Meeting/Dividend - Rs 2/- Per Share | 20-Sep-2017 |
| 1 | Annual General Meeting/ Dividend - Rs 2/- Per Share | 03-Aug-2016 |
| 1 | Annual General Meeting/ Dividend - Rs 2/- Per Share | 10-Sep-2015 |
| 1 | Annual General Meeting / Dividend - Rs 2/- Per Share | 10-Jul-2014 |
| 1 | Annual General Meeting / Dividend - Rs 2/- Per Share | 18-Jul-2013 |
| 1 | Annual General Meeting / Dividend Rs 2 Per Share | 19-Jul-2012 |
| 1 | Annual General Meeting And Dividend Re.0.40 Per Share | 28-Jul-2011 |
| 1 | Annual General Meeting And Dividend Re.0.40 Per Share | 16-Sep-2010 |
| 1 | Agm/Div-Re.0.40 Per Share | 10-Sep-2009 |
| 1 | Annual General Meeting | 18-Sep-2008 |
| 1 | Interim Dividend-70% Purpose Revised | 07-Nov-2007 |
| 1 | Agm/Fv Split Rs.2 To Re.1 | 10-Sep-2007 |
| 1 | Interim Dividend - 40% | 04-Jan-2007 |
Board Meetings of Glenmark Pharmaceuticals Limited
Financial Results of Glenmark Pharmaceuticals Limited
Company Directory of Glenmark Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.glenmarkpharma.com | Head Office/ Corporate Office | Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E | MUMBAI |
| www.glenmarkpharma.com | Registered Office | B/2, Mahalaxmi Chambers 22, Bhulabhai Desai Road | MUMBAI |
| www.glenmarkpharma.com | Transfer Agent | M/s Karvy Computershare (P) Limited Plot No. 17-24, Vithal Rao Nagar, Madhapur, | HYDERABAD |
Insider Trading of Glenmark Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Mr. Praveen D Kurkal | 425510 | Sell |
| 7(2) | Mr. Praveen D Kurkal | 852000 | Sell |
| 7(2) | Mr. Praveen D Kurkal | 852000 | Sell |
| 7(2) | Robin Pinto | 122548 | Buy |
| 7(2) | SRIDHAR GORTHI | 299447 | Sell |
| 7(2) | AISHA LOUISE SALDANHA | 0 | Sell |
| 7(2) | NEHA SALDANHA | 0 | Buy |
| 7(2) | RAYNA MARIE SALDANHA | 0 | Sell |
| 7(2) | Glenn Mario Saldanha | 5027549 | Buy |
| 7(2) | Cherylann Maria Pinto | 1000087 | Buy |
| 7(2) | Glenn Mario Saldanha | 4992000 | Buy |
| 7(2) | Glenn Mario Saldanha | 1797197 | Buy |
| 7(2) | Glenn Mario Saldanha | 5011943 | Buy |
| 7(2) | AISHA LOUISE SALDANHA | 4877192 | Buy |
| 7(2) | RAYNA MARIE SALDANHA | 4877519 | Buy |
| 7(2) | Robin Pinto | 372203 | Buy |
| 7(2) | Robin Pinto | 112832 | Buy |
| 7(2) | Robin Pinto | 116254 | Buy |
| 7(2) | Robin Pinto | 239705 | Buy |
| 7(2) | Robin Pinto | 250236 | Buy |
Annual Reports of Glenmark Pharmaceuticals Limited
Investor Complaints of Glenmark Pharmaceuticals Limited
Event Calendar of Glenmark Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Bonus | To consider issue of Bonus shares. |
| Results/Dividend | Inter alia, to consider the following : (1) To consider and approve the Company's audited financial statements for the 4th quarter and year ended March 31, 2010; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2010. |
| Results/Dividend | (1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2011; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2011. |
| Results/Dividend | (1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2012; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2012. |
| Financial Results | To consider and approve the Company's Unaudited Financial Statements for the quarter ended June 30, 2012. |
| Results/Dividend | 1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2013. 2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2013. |
| Results | To consider and approve the Company's Un-audited Financial Statements for the First Quarter ended 30th June, 2013. |
| Results | to consider and approve the Company's un-audited Financial Statements for the Second Quarter/Half year ended September 30, 2013. |
| Results | To consider and approve the Company's Un-audited Financial Statements for the Third Quarter ended December 31, 2013. |
| Results/Dividend | 1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2014. 2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2014. Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from April 28, 2014 to May 09, 2014 (both days inclusive) for the purpose of approval of Audited Financial Results for the year ended March 31, 2014. |
| Results | To consider and approve the Company's Un-audited Financial Statements for the First Quarter ended June 30, 2014. |
| Results | To consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half year ended September 30, 2014. Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from October 17, 2014 to October 31, 2014 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter/Half year ended September 30, 2014. |
| Results | to consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2014. |
| Results/Dividend | 1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2015. 2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2015. |
| Results | to consider and approve the Company s Unaudited Financial Statements for the First Quarter ended June 30, 2015. |
| Results | to consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half Year ended September 30, 2015. |
| Results | to consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2015. |
| Results/Dividend | 1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2016.2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2016. |
| Results | To consider and approve the Company s Unaudited Financial Statements for the First Quarter ended June 30, 2016. |
| Results | to consider and approve the Company s Unaudited Financial Statements for the Second Quarter/Half Year ended September 30, 2016. |
| Results | to consider and approve the Company s Unaudited Financial Statements for the Third Quarter and Nine months ended December 31, 2016. |
| Results/Dividend | to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2017. |
| Results | to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2017. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half year ended September 30, 2017. |
| Results | inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Other business matters | Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt |
| Financial Results | to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, May 29, 2019, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2019 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2019.Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from April 1, 2019 to May 31, 2019 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the year ended March 31, 2019. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2019 |
| Fund Raising | We have to inform you that the Board of Directors of the Company, at its meeting scheduled on February 14, 2020, will, inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, of any of the above, for refinancing of bonds/FCCBs/loans, in accordance with the FEMA ECB Guidelines, and other applicable regulations, guidelines and laws of India, and subject to all necessary regulatory, statutory and shareholder approvals, as may be required. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Other business matters | Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt |
| Financial Results/Dividend | We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, May 28, 2021, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2021 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2021.ￂﾠFurther, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31, 2021 to May 30, 2021 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2021.ￂﾠￂﾠ |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Glenmark Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 10-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Board Meeting Intimation For Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2022. |
| Financial Results | Board Meeting intimation for Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2022. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Glenmark Pharmaceuticals Limited
Voting Results of Glenmark Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 27-SEP-2024 | AGM | To receive, consider, approve and adopt the Audited Standalone Financial Statements for the Financial Year ended 31 March 2024 together with the reports of the Board and Auditors thereon. |
| 27-SEP-2024 | AGM | To ratify remuneration of the cost auditor for the financial year ending 31 March 2025. |
| 27-SEP-2024 | AGM | To appoint a Director in place of Mr. Glenn Saldanha (DIN 00050607), who retires by rotation and being eligible, offers himself for re-appointment. |
| 27-SEP-2024 | AGM | To declare dividend of Rs. 2.50/- per equity share for the financial year 31 March 2024. |
| 27-SEP-2024 | AGM | To receive, consider, approve and adopt the Audited Consolidated Financial Statements for the Financial Year ended 31 March 2024 together with the report of the Auditors thereon. |
| 07-NOV-2023 | Postal Ballot | To consider and approve the sale of equity shares of Glenmark Life Sciences Limited, a Material Subsidiary of the Company |
| 29-SEP-2023 | AGM | To receive, consider, approve and adopt the Audited Standalone Financial Statements for the Financial Year ended 31 March 2023 together with the reports of the Board and Auditors thereon |
| 29-SEP-2023 | AGM | To re-appoint Ms. Sona Saira Ramasastry as an Independent Director of the Company |
| 29-SEP-2023 | AGM | To ratify remuneration of the cost auditor for the financial year ending 31 March 2024 |
| 29-SEP-2023 | AGM | To re-appoint Mrs. Blanche Saldanha as director liable to retire by rotation |
| 29-SEP-2023 | AGM | To declare dividend on Equity Shares. |
| 29-SEP-2023 | AGM | To receive, consider, approve and adopt the Audited Consolidated Financial Statements for the Financial Year ended 31 March 2023 together with the report of the Auditors thereon. |
| 04-AUG-2023 | Postal Ballot | Re-appointment of Mr V. S. Mani (DIN: 01082878) as an Executive Director & Global Chief Financial Officer of the Company |
| 14-APR-2023 | Postal Ballot | Appointment of Mrs. Vijayalakshmi Rajaram Iyer (DIN:05242960) as Non-Executive ￢ﾀﾓ Independent Director |
| 27-SEP-2022 | AGM | To receive, consider, approve and adopt the Audited Standalone Financial Statements for the Financial Year ended 31 March 2022 together with the reports of the Board and Auditors thereon |
| 27-SEP-2022 | AGM | To ratify remuneration of the cost auditor for the financial year ending 31 March, 2023 |
| 27-SEP-2022 | AGM | To appoint a Director in place of Mr. V.S. Mani (DIN 01082878) who retires by rotation and being eligible, offers himself for re-appointment as per Section 152(6) of the Companies Act, 2013 |
| 27-SEP-2022 | AGM | To declare dividend on Equity Shares |
| 27-SEP-2022 | AGM | To receive, consider, approve and adopt the Audited Consolidated Financial Statements for the Financial Year ended 31 March 2022 together with the report of the Auditors thereon |
| 14-MAY-2022 | Postal Ballot | Re-appointment of Mr. Glenn Saldanha (DIN 00050607) as the Chairman & Managing Director |
FAQs on Glenmark Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.